Affordable Access

Access to the full text

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Authors
  • Tinoco, Lygia Accioly1
  • Ferreira, Karla Cristina Marques Afonso2
  • Almeida, Cenusa1
  • Angus, Brian3
  • Arns, Beatriz4
  • Arruda, Laiana1
  • De Ávila Kfouri, Renato5
  • da Silva, Lucas Henrique Azevedo2
  • Moreira, Matheus José Barbosa2
  • Paiva, Brenda Vasconcelos Barbosa6, 7
  • Bates, Louise3
  • Bellei, Nancy5
  • Boettger, Bruno5
  • Lora, Leandro Bonecker6, 7
  • de Araújo, Nina Amanda Borges2
  • de Oliveira, Chrystiane do Nascimento Br...2
  • Brown-O’Sullivan, Charlie3
  • Luz, Daniel Calich2
  • Mourão, Joao Renato Cardoso6, 7
  • Carvalho, Caroline Scherer8
  • And 71 more
Type
Published Article
Journal
Nature Communications
Publisher
Springer Nature
Publication Date
Oct 05, 2021
Volume
12
Issue
1
Identifiers
DOI: 10.1038/s41467-021-25982-w
Source
Springer Nature
License
Green

Abstract

Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.

Report this publication

Statistics

Seen <100 times